dammarenediol: RN refers to (3beta)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 122880 |
| MeSH ID | M0276785 |
| Synonym |
|---|
| (3s,5r,8r,9r,10r,14r)-17-[(1s)-1-hydroxy-1,5-dimethyl-hex-4-enyl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol |
| (20s)-dammar-24-ene-3 beta,20-diol |
| dammar-24-ene-3,20-diol, (3.beta.)- |
| 14351-29-2 |
| (3s,5r,8r,9r,10r,14r)-17-((s)-1-hydroxy-1,5-dimethyl-hex-4-enyl)-4,4,8,10,14-pentamethyl-hexadecahydro-cyclopenta[a]phenanthren-3-ol |
| dammarenediol |
| (3s,5r,8r,9r,10r,14r)-17-[(2s)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol |
| A808335 |
| (3s,5r,8r,9r,10r,14r)-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-oxidanyl-hept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol |
| dammar-24-ene-3,20-diol, (3beta)- |
| DTXSID50931936 |
| dammar-24-ene-3,20-diol |
Dammarenediol-II is a useful candidate both for pharmacologically active triterpenes and as a defense compound in plants.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dammarenediol synthase (DS) is a key enzyme in the saponin synthesis pathway of P." | ( Activity and function studies of the promoter cis-acting elements of the key enzymes in saponins biosynthesis of DS from Panax notoginseng. Liang, Z; Shao, R; Xia, P; Yan, K; Zheng, Y, 2022) | 1.44 |
| "Dammarenediol-II is a useful candidate both for pharmacologically active triterpenes and as a defense compound in plants." | ( Production of dammarenediol-II triterpene in a cell suspension culture of transgenic tobacco. Choi, YE; Han, JY; Wang, HY, 2014) | 1.48 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.26) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||